Petros Pharma reports 2021 net sales $7.8M, net loss down 56% to $9.0M

Petros Pharmaceuticals, Inc.

2022-Q1 EPS reported -$0.01 revenue$2,465,169

Net sales $7.8M vs $9.6M in 2020; prescription sales fell to $4.6M due to competitive coupons.
Gross profit up 13% to $6.2M on lower write-offs and fulfillment costs; SG&A flat at $15.6M.
Net loss improved to $9.0M from $20.6M, largely from reduced fair value derivative liability.
Cash at year-end ~$24M; pursuing OTC switch for STENDRA with two self-selection studies launched.
Collaboration with Dr. Drew Pinsky to raise men's health awareness; H100 Peyronie's license expanded.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.